Avinger, Inc., a Redwood City, CA-based medical device manufacturer of catheters for treating patients with Peripheral Artery Disease (PAD), has closed a $33m Series D funding.
Existing major investors participated in the round, with new investors contributing over $11m.
Founded in 2007 by by Dr. John B. Simpson, CEO, Avinger leverages core competencies in medical device catheter engineering and intravascular Optical Coherence Tomography (OCT) to develop catheter-based technologies for the treatment of peripheral artery disease (PAD). It markets Wildcat and Kittycat catheters, and in 2011 received CE Mark to market Ocelot, a real-time OCT crossing catheter.
The company intends to use the new funds for its R&D efforts around Wolverine, its peripheral atherectomy catheter that also incorporates intravascular imaging technology using Optical Coherence Tomography (OCT).